ArticleMedical physics2026
Biomechanical mapping of tumor growth: A novel method to quantify glioma infiltration and mass effect.
Article in Medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomechanical mapping of tumor growth: A novel method to quantify glioma infiltration and mass effect.Medical physics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) growth can alter surrounding brain tissue through location-dependent physiological changes. Two main growth phenotypes-(I) infiltrative, characterized by diffuse invasion with minimal mass effect, and (II) proliferative, characterized by pronounced tissue compression-are recognized, but their quantitative characterization and prognostic impact remain poorly explored. PURPOSE: To develop and validate a novel MRI-based biomarker, the Dynamic Infiltration Rate (DIR), that quantitatively assesses the balance between tumor volume expansion and peritumoral compression, and to evaluate its prognostic ability for stratifying patients based on overall survival (OS).
methodsThe DIR was defined as the ratio between tumor-volume enlargement and mass-effect-induced peritumoral compression. Technical validation was conducted using synthetic datasets with known ground truth spanning realistic infiltrative-proliferative spectra. Clinically, patients were dichotomized into high- and low-infiltration groups using a threshold optimized by maximizing the log-rank statistic for OS. Prognostic evaluation included multivariate Cox regression adjusted for age, sex, and MGMT methylation status.
resultsThe synthetic dataset validation demonstrated high concordance with ground truth (
conclusionsThe DIR is a novel and robust quantitative MRI biomarker capable of distinguishing between proliferative and infiltrative GBM phenotypes, independently predicting OS. Early phenotype identification could facilitate personalized treatment strategies and individualized follow-up scheduling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.